Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday

Karyopharm Therapeutics (NASDAQ:KPTI) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $37.83 million for the quarter. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Karyopharm Therapeutics Trading Up 14.8 %

Shares of NASDAQ:KPTI opened at $9.83 on Thursday. Karyopharm Therapeutics has a 1 year low of $7.61 and a 1 year high of $25.50. The firm has a fifty day moving average price of $0.84 and a 200 day moving average price of $0.82. The stock has a market capitalization of $1.24 billion, a PE ratio of -9.64 and a beta of 0.06.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KPTI. Piper Sandler increased their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. HC Wainwright increased their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Finally, StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.25.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).